Skip to content

Pipeline

Product Indication Industry Partners Status
RESTASIS® (EU) Ocular Surface Disease
- Phase 3
RESTASIS® X Ocular Surface Disease
- Phase 2
NOVADUR® (Brimonidine) Retinal Diseases
- Phase 2
AGN 208397 Retinal Diseases
- Phase 2
Bimatoprost Sustained Release Glaucoma
- Phase 2
AGN 150998 (Anti-VEGF DARPin®) Age-Related Macular Degeneration
- Phase 2
Anti-VEGF/PDGF-B DARPin® Age-Related Macular Degeneration
- Pre-Clinical
TKI Age-Related Macular Degeneration
- Pre-Clinical
Product Indication Industry Partners Status
LEVADEX® Migraine - Acute Therapy
- Filed
BOTOX® Juvenile Cerebral Palsy
- Phase 3
TEM Pain
- Phase 2
BOTOX® Osteoarthritis Pain
- Phase 2
BOTOX® Depression
- Phase 2
Product Indication Industry Partners Status
SER-120 Nocturia
Serenity Pharmaceuticals, LLC Phase 3
BOTOX® Premature Ejaculation
- Phase 2
Product Indication Industry Partners Status
ACZONE® X Acne
- Phase 3
AGN-199201 (Oxymetazoline) Rosacea
- Phase 3
Product Indication Industry Partners Status
LATISSE® Brow
- Phase 3
Bimatoprost Scalp
- Phase 2
Product Indication Industry Partners Status
JUVÉDERM VOLBELLA® (U.S.) Facial Aesthetics
- Clinical
JUVÉDERM VOLIFT® (U.S.) Facial Aesthetics
- Clinical